Viser 51 - 87 av 87 resultater
Tid Selskap Tittel Sektor Kategori
14 Nov 2023
22:00 CET
CELYAD ONCOLOGY Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) 20103010 Biotechnology Other subject
14 Nov 2023
22:00 CET
CELYAD ONCOLOGY Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007) 20103010 Biotechnology Other subject
09 Nov 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology publie ses résultats financiers pour le troisième trimestre de 2023 ainsi que ses récentes avancées 20103010 Biotechnology Corporate life
09 Nov 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology reports third quarter 2023 financial results and recent business highlights 20103010 Biotechnology Corporate life
25 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology Announces the Termination of Its American Depository Receipt Program 20103010 Biotechnology Other subject
25 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology annonce l’arrêt de son programme d’American Depositary Receipt 20103010 Biotechnology Other subject
15 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA : Publication d’une notification de transparence rectifiée de Fortress Investment Group LLC 20103010 Biotechnology Other subject
15 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC 20103010 Biotechnology Other subject
12 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA : Publication d’une notification de transparence reçue de Tolefi SA 20103010 Biotechnology Other subject
12 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA 20103010 Biotechnology Other subject
07 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC 20103010 Biotechnology Other subject
07 Sep 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology SA : Notification de transparence de Fortress Investment Group LLC 20103010 Biotechnology Other subject
05 Sep 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology SA:Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) 20103010 Biotechnology Other subject
05 Sep 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007) 20103010 Biotechnology Other subject
04 Sep 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights 20103010 Biotechnology Other subject
04 Sep 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology Présente ses Résultats Financiers pour le Premier Semestre de l’année 2023 et les Récents Evénements Marquants de son Activité 20103010 Biotechnology Other subject
29 Aug 2023
18:00 CEST
CELYAD ONCOLOGY Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical Shareholders 20103010 Biotechnology Share introduction and issues
15 May 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology annonce la réception d’un avis de radiation du Nasdaq 20103010 Biotechnology Other subject
15 May 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology Announces Receipt of Nasdaq Delisting Notice 20103010 Biotechnology Other subject
05 May 2023
07:44 CEST
CELYAD ONCOLOGY Celyad Oncology annonce son intention de radier les American Depositary Shares de la Société du Nasdaq 20103010 Biotechnology New
05 May 2023
07:44 CEST
CELYAD ONCOLOGY Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq 20103010 Biotechnology New
05 May 2023
07:42 CEST
CELYAD ONCOLOGY Celyad Oncology publie ses résultats financiers pour le premier trimestre de 2023 ainsi que ses récentes avancées 20103010 Biotechnology New
05 May 2023
07:42 CEST
CELYAD ONCOLOGY Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business Highlights 20103010 Biotechnology New
24 Apr 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology annonce la réception d’une notification initiale du Nasdaq sur le prix de l’ADS 20103010 Biotechnology Legal
24 Apr 2023
22:01 CEST
CELYAD ONCOLOGY Celyad Oncology Announces Receipt of Nasdaq Initial Notification on ADS Bid Price 20103010 Biotechnology Legal
04 Apr 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology annonce la réception d’une notification du Nasdaq 20103010 Biotechnology Other subject
04 Apr 2023
22:00 CEST
CELYAD ONCOLOGY Celyad Oncology announces receipt of Nasdaq notice 20103010 Biotechnology Other subject
24 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology nomme Georges Rawadi comme nouveau CEO 20103010 Biotechnology Corporate life
24 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology Appoints Georges Rawadi as Its New CEO 20103010 Biotechnology Corporate life
23 Mar 2023
22:01 CET
CELYAD ONCOLOGY Celyad Oncology publie ses résultats financiers pour l'année 2022 ainsi que les récents évènements marquants 20103010 Biotechnology Other subject
23 Mar 2023
22:01 CET
CELYAD ONCOLOGY Celyad Oncology Reports Full Year 2022 Financial Results and Recent Business Highlights 20103010 Biotechnology Other subject
17 Mar 2023
22:01 CET
CELYAD ONCOLOGY Celyad Oncology annoncera prochainement ses résultats opérationnels et financiers 2022 et organisera une conférence téléphonique 20103010 Biotechnology Other subject
17 Mar 2023
22:01 CET
CELYAD ONCOLOGY Celyad Oncology to Announce Full Year 2022 Financial Results and Host Conference Call 20103010 Biotechnology Other subject
15 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad annonce une réduction de valeur non monétaire 20103010 Biotechnology Change in Capital
15 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology Announces Non-Cash Impairment 20103010 Biotechnology Change in Capital
01 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology: Letter to Shareholders 20103010 Biotechnology Corporate life
01 Mar 2023
07:00 CET
CELYAD ONCOLOGY Celyad Oncology : Lettre aux Actionnaires 20103010 Biotechnology Corporate life